Biontech SE
BNTX107.500USD
-2.550-2.32%
Fechamento 07/31, 16:00（ET）Cotações atrasadas em 15 min
25.84BValor de mercado
PerdaP/L TTM
Mais detalhes de Biontech SE Empresa
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Informações da empresa
Código da empresaBNTX
Nome da EmpresaBiontech SE
Data de listagemOct 10, 2019
Fundado em2019
CEOProf. Ugur Sahin, M.D.
Número de funcionários6772
Tipo de títulosDepository Receipt
Fim do ano fiscalOct 10
EndereçoAn der Goldgrube 12
CidadeMAINZ
Bolsa de valoresNASDAQ Global Select Consolidated
PaísGermany
Código postal55131
Telefone4949613190840
Sitehttps://www.biontech.com/
Código da empresaBNTX
Data de listagemOct 10, 2019
Fundado em2019
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+1.69%
Mr. Ryan Richardson
Mr. Ryan Richardson
Chief Strategy Officer, Member of the Management Board
Chief Strategy Officer, Member of the Management Board
26.55K
+80.66%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
--
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Ramon Zapata Gomez
Ramon Zapata Gomez
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Helmut Jeggle
Mr. Helmut Jeggle
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
--
--
Dr. Oezlem Tuereci, M.D.
Dr. Oezlem Tuereci, M.D.
Chief Medical Office, Member of the Management Board
Chief Medical Office, Member of the Management Board
--
--
Ms. Baroness Nicola Blackwood
Ms. Baroness Nicola Blackwood
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+1.69%
Mr. Ryan Richardson
Mr. Ryan Richardson
Chief Strategy Officer, Member of the Management Board
Chief Strategy Officer, Member of the Management Board
26.55K
+80.66%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
--
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Detalhamento da receita
Moeda: EURAtualizado em: qua, 12 de mar
Moeda: EURAtualizado em: qua, 12 de mar
FY2019
FY2018
FY2017
Por EmpresaEUR
Nome
Receita
Proporção
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
Sem dados
Por Empresa
Por Região
Por EmpresaEUR
Nome
Receita
Proporção
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
Distribuição de ações
Atualizado em: sáb, 19 de jul
Atualizado em: sáb, 19 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
AT Impf GmbH
42.37%
Medine GmbH
16.69%
Baillie Gifford & Co.
3.39%
Fidelity Management & Research Company LLC
2.48%
Flossbach von Storch AG
1.77%
Other
33.30%
Investidores
Investidores
Proporção
AT Impf GmbH
42.37%
Medine GmbH
16.69%
Baillie Gifford & Co.
3.39%
Fidelity Management & Research Company LLC
2.48%
Flossbach von Storch AG
1.77%
Other
33.30%
Tipos de investidores
Investidores
Proporção
Corporation
60.58%
Investment Advisor
15.28%
Investment Advisor/Hedge Fund
3.60%
Individual Investor
2.11%
Hedge Fund
1.18%
Research Firm
1.17%
Sovereign Wealth Fund
0.75%
Pension Fund
0.23%
Bank and Trust
0.17%
Other
14.94%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
811
205.04M
85.29%
-4.48M
2025Q1
851
205.71M
85.57%
-4.55M
2024Q4
869
205.33M
85.56%
+3.19M
2024Q3
843
197.46M
82.52%
-2.61M
2024Q2
819
194.42M
81.78%
-7.50M
2024Q1
835
193.57M
81.42%
-10.02M
2023Q4
897
193.24M
81.29%
-7.90M
2023Q3
920
192.71M
79.62%
-7.47M
2023Q2
940
195.49M
80.61%
-8.54M
2023Q1
953
197.88M
81.52%
-6.52M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
AT Impf GmbH
101.85M
42.37%
-636.54K
-0.62%
Dec 31, 2024
Medine GmbH
40.13M
16.69%
-304.48K
-0.75%
Mar 31, 2025
Baillie Gifford & Co.
8.16M
3.39%
-60.90K
-0.74%
Mar 31, 2025
Fidelity Management & Research Company LLC
5.95M
2.48%
-495.85K
-7.69%
Mar 31, 2025
Flossbach von Storch AG
4.26M
1.77%
-147.21K
-3.34%
Mar 31, 2025
PRIMECAP Management Company
4.05M
1.68%
-249.39K
-5.81%
Mar 31, 2025
Pfizer Inc
3.66M
1.52%
--
--
Mar 31, 2025
Sahin (Ugur MD)
2.05M
0.85%
-724.50K
-26.11%
Mar 31, 2025
Temasek Holdings Pte. Ltd.
1.81M
0.75%
--
--
Mar 31, 2025
Capital International Investors
1.43M
0.59%
+12.88K
+0.91%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: dom, 6 de jul
Atualizado em: dom, 6 de jul
Nome
Proporção
iShares Genomics Immunology and Healthcare ETF
3.94%
Langar Global HealthTech ETF
3.81%
Global X Genomics & Biotechnology ETF
3.56%
First Trust NYSE Arca Biotechnology Index Fund
3.12%
Franklin Genomic Advancements ETF
2.89%
VanEck Biotech ETF
2.66%
Virtus LifeSci Biotech Products ETF
2.02%
iShares Biotechnology ETF
1.65%
WisdomTree BioRevolution Fund
1.57%
ProShares Ultra Nasdaq Biotechnology
1.21%
Ver Mais
iShares Genomics Immunology and Healthcare ETF
Proporção3.94%
Langar Global HealthTech ETF
Proporção3.81%
Global X Genomics & Biotechnology ETF
Proporção3.56%
First Trust NYSE Arca Biotechnology Index Fund
Proporção3.12%
Franklin Genomic Advancements ETF
Proporção2.89%
VanEck Biotech ETF
Proporção2.66%
Virtus LifeSci Biotech Products ETF
Proporção2.02%
iShares Biotechnology ETF
Proporção1.65%
WisdomTree BioRevolution Fund
Proporção1.57%
ProShares Ultra Nasdaq Biotechnology
Proporção1.21%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
